| scholarly article | Q13442814 |
| P2093 | author name string | Sigrun Lange | |
| Dan Stratton | |||
| Ephraim A Ansa-Addo | |||
| Jameel M Inal | |||
| Sharad Kholia | |||
| Antwi-Baffour, S. | |||
| Lange, S. | |||
| Stratton, D. | |||
| Ansa-Addo, E.A. | |||
| Aryee, Y.K. | |||
| Inal, J.M. | |||
| Kholia, S. | |||
| Samuel Antwi-Baffour | |||
| Yushau K-D Aryee | |||
| P433 | issue | 2 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | phagocytosis | Q184726 |
| antiphospholipid antibodies | Q582142 | ||
| apoptotic process | Q14599311 | ||
| P304 | page(s) | 278-283 | |
| P577 | publication date | 2010-01-01 | |
| 2010-06-23 | |||
| P1433 | published in | Biochemical and Biophysical Research Communications | Q864228 |
| P1476 | title | Human plasma membrane-derived vesicles inhibit the phagocytosis of apoptotic cells--possible role in SLE. | |
| P478 | volume | 398 |
| Q38443364 | A novel role for peptidylarginine deiminases in microvesicle release reveals therapeutic potential of PAD inhibition in sensitizing prostate cancer cells to chemotherapy |
| Q58785789 | Cannabidiol (CBD) Is a Novel Inhibitor for Exosome and Microvesicle (EMV) Release in Cancer |
| Q60929868 | Cannabidiol Affects Extracellular Vesicle Release, miR21 and miR126, and Reduces Prohibitin Protein in Glioblastoma Multiforme Cells |
| Q38657043 | Clinical Risk Assessment in the Antiphospholipid Syndrome: Current Landscape and Emerging Biomarkers |
| Q38114752 | Current methods for the isolation of extracellular vesicles. |
| Q21195358 | Disturbances of apoptotic cell clearance in systemic lupus erythematosus |
| Q38191663 | Emerging technologies in extracellular vesicle-based molecular diagnostics |
| Q40365709 | Enhanced activation of dendritic cells by autologous apoptotic microvesicles in MRL/lpr mice |
| Q38012446 | Exosome mimetics: a novel class of drug delivery systems |
| Q30404427 | Inhibition of microvesiculation sensitizes prostate cancer cells to chemotherapy and reduces docetaxel dose required to limit tumor growth in vivo. |
| Q38077237 | Interplay of host-pathogen microvesicles and their role in infectious disease. |
| Q26795583 | Microparticles That Form Immune Complexes as Modulatory Structures in Autoimmune Responses |
| Q34991385 | Microparticles provide a novel biomarker to predict severe clinical outcomes of dengue virus infection |
| Q38077236 | Microvesicles and exosomes as vehicles between protozoan and host cell communication |
| Q37981578 | Microvesicles in health and disease. |
| Q38077234 | Microvesiculation and disease. |
| Q39354673 | Peptidylarginine Deiminases-Roles in Cancer and Neurodegeneration and Possible Avenues for Therapeutic Intervention via Modulation of Exosome and Microvesicle (EMV) Release? |
| Q55331760 | Potential Involvement of Platelet-Derived Microparticles and Microparticles Forming Immune Complexes during Monocyte Activation in Patients with Systemic Lupus Erythematosus. |
| Q37776868 | Red cell PMVs, plasma membrane-derived vesicles calling out for standards |
| Q41923180 | T lymphocytes export proteasomes by way of microparticles: a possible mechanism for generation of extracellular proteasomes |
| Q94070955 | The Role of Microparticles in Rheumatic Diseases and their Potentials as Therapeutic Tools |
| Q37799738 | The immune functions of phosphatidylserine in membranes of dying cells and microvesicles. |
Search more.